Organon Reports Q2 2023 Revenue Growth, Driven by Women’s Health and Biosimilars
US-based Organon (NYSE: OGN) has reported its financial results for the second quarter of 2023,...
Organon
Organon Reports Q1 2023 Revenue Growth, Highlights Women’s Health and Biosimilars Progress
Organon (NYSE: OGN) has released its financial report for the first quarter of 2023, announcing...
Organon Reports Q4 and Full-Year 2022 Financials with Revenue Declines
US-based Organon Inc. (NYSE: OGN) has released its Q4 and full-year 2022 financial results. Global...
Organon Partners with Alibaba Health to Enhance Chronic Disease Management
Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that...
Organon Sponsors Retail Pharmacy Health Center at CIIE
The 5th China International Import Expo (CIIE) saw Organon & Co. (NYSE: OGN), a firm...
Organon’s Q3 Results Show Women’s Health Segment Outperforms Amid Global Revenue Decline
US-based Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health...
Organon Signs MOU with China’s National Health Commission at CIIE
Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that...
Organon’s China Head Shi Wang Departs to Lead Sanofi Greater China
Women’s health specialist Organon (NYSE: OGN) announced the departure of its former China unit head...
Shanghai Henlius Partners with Organon for Global Biosimilar Commercialization
China-based Shanghai Henlius Biotech, Inc. (HKG: 2696) has entered into a licensing and supply agreement...